Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pinky Dua

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Clinical Pharmacology and Therapeutics|December 11, 2023
Comparative Effectiveness of Bimekizumab in Psoriatic Arthritis: A Model-Based Meta-Analysis of American College of Rheumatology Response CriteriaAlan Maloney, Pinky Dua, Ghada F Ahmed
Medical & Biological Engineering & Computing|April 21, 2010
Modelling and multi-parametric control for delivery of anaesthetic agentsPinky Dua, Vivek Dua, Efstratios N Pistikopoulos
IEEE Transactions on Bio-Medical Engineering|August 19, 2006
Model-based blood glucose control for Type 1 diabetes via parametric programmingPinky Dua, Francis J Doyle, Efstratios N Pistikopoulos
Medical & Biological Engineering & Computing|February 14, 2009
Multi-objective blood glucose control for type 1 diabetesPinky Dua, Francis J Doyle, Efstratios N Pistikopoulos
Clinical Rheumatology|April 21, 2016
Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649Pinky Dua, Rachel Gurrell, Simon Kirby, et al.
Clinical Pharmacology and Therapeutics|September 14, 2022
Population PK and PD Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular DystrophyJessica Wojciechowski, Vivek S Purohit, Lutz O Harnisch, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 2, 2024
Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseasesDenis Menshykau, Jagdev Sidhu, Laura Shaughnessy, et al.
Pain|May 23, 2018
A randomised, placebo-controlled clinical trial with the α2/3/5 subunit selective GABAA positive allosteric modulator PF-06372865 in patients with chronic low back painRachel Gurrell, Pinky Dua, Gang Feng, et al.
Frontiers in Medicine|June 16, 2018
Physiology of Hyperuricemia and Urate-Lowering TreatmentsCaroline L Benn, Pinky Dua, Rachel Gurrell, et al.
Journal of Clinical Psychopharmacology|December 12, 2018
An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety DisorderArthur Simen, Mark Whitlock, Ruolun Qiu, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Clinical Pharmacology and Therapeutics|December 11, 2023
Comparative Effectiveness of Bimekizumab in Psoriatic Arthritis: A Model-Based Meta-Analysis of American College of Rheumatology Response CriteriaAlan Maloney, Pinky Dua, Ghada F Ahmed
Medical & Biological Engineering & Computing|April 21, 2010
Modelling and multi-parametric control for delivery of anaesthetic agentsPinky Dua, Vivek Dua, Efstratios N Pistikopoulos
IEEE Transactions on Bio-Medical Engineering|August 19, 2006
Model-based blood glucose control for Type 1 diabetes via parametric programmingPinky Dua, Francis J Doyle, Efstratios N Pistikopoulos
Medical & Biological Engineering & Computing|February 14, 2009
Multi-objective blood glucose control for type 1 diabetesPinky Dua, Francis J Doyle, Efstratios N Pistikopoulos
Clinical Rheumatology|April 21, 2016
Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649Pinky Dua, Rachel Gurrell, Simon Kirby, et al.
Clinical Pharmacology and Therapeutics|September 14, 2022
Population PK and PD Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular DystrophyJessica Wojciechowski, Vivek S Purohit, Lutz O Harnisch, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 2, 2024
Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseasesDenis Menshykau, Jagdev Sidhu, Laura Shaughnessy, et al.
Pain|May 23, 2018
A randomised, placebo-controlled clinical trial with the α2/3/5 subunit selective GABAA positive allosteric modulator PF-06372865 in patients with chronic low back painRachel Gurrell, Pinky Dua, Gang Feng, et al.
Frontiers in Medicine|June 16, 2018
Physiology of Hyperuricemia and Urate-Lowering TreatmentsCaroline L Benn, Pinky Dua, Rachel Gurrell, et al.
Journal of Clinical Psychopharmacology|December 12, 2018
An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety DisorderArthur Simen, Mark Whitlock, Ruolun Qiu, et al.
Pageof 2